[go: up one dir, main page]

NO920855L - Medikamentinneholdende matrise - Google Patents

Medikamentinneholdende matrise

Info

Publication number
NO920855L
NO920855L NO92920855A NO920855A NO920855L NO 920855 L NO920855 L NO 920855L NO 92920855 A NO92920855 A NO 92920855A NO 920855 A NO920855 A NO 920855A NO 920855 L NO920855 L NO 920855L
Authority
NO
Norway
Prior art keywords
patient
lollipop
drug
lipophilic
medicine
Prior art date
Application number
NO92920855A
Other languages
English (en)
Other versions
NO920855D0 (no
Inventor
Theodore Stanley
Brian Hague
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of NO920855D0 publication Critical patent/NO920855D0/no
Publication of NO920855L publication Critical patent/NO920855L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Fremgangsmåter og sammensetninger for ikke-invasiv administrering av mediliamenteter på en dose til effekt måte for å gl en kardiovaskulær eller en nyrevaskulær aktivitet. Et kardlovaskulært eller nyrevaskulært medikament som er l stand til å bil absorbert gjennom \'r*~Z'> sllmhlnnevevene l munnen, svelget og spiserøret blir innarbeidet i en matrise som er i form av en sllkke- plnne. En pasient blir beroliget ved å få sllkkepinnen og medlkamentet går raskt Inn l pasientens blodstrøm etter som sllkkepinnen blir sugd på. ved behandling av pasienten, kan legen observere pasientens tilstand og fjerne sllkkepinnen når den har hatt den ønskede effekt for pasienten. En sllkkeplnne l hvilken et kardlo- vaskulært eller nyrevaskulært medikament har blitt spredd, er spesielt nyttig for å oppnå hurtig vaso- dllaterende, kalsium kanal blokkerende, beta-blokk- erende, seritonin resepter blokkerende, angina blokkerende, antl-hypertenslvé og hjertestimulerende effekter og for kontrollerlng av urlnmengde.
NO92920855A 1989-09-05 1992-03-04 Medikamentinneholdende matrise NO920855L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1989/003801 WO1991003233A1 (en) 1989-09-05 1989-09-05 Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs

Publications (2)

Publication Number Publication Date
NO920855D0 NO920855D0 (no) 1992-03-04
NO920855L true NO920855L (no) 1992-04-10

Family

ID=22215208

Family Applications (2)

Application Number Title Priority Date Filing Date
NO92920855A NO920855L (no) 1989-09-05 1992-03-04 Medikamentinneholdende matrise
NO92920854A NO920854L (no) 1989-09-05 1992-03-04 Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO92920854A NO920854L (no) 1989-09-05 1992-03-04 Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter

Country Status (8)

Country Link
EP (1) EP0493380B1 (no)
JP (1) JP2758985B2 (no)
AT (1) ATE159658T1 (no)
AU (2) AU645966B2 (no)
DE (1) DE68928415T2 (no)
DK (1) DK175773B1 (no)
NO (2) NO920855L (no)
WO (1) WO1991003233A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624011A5 (no) * 1977-08-05 1981-07-15 Battelle Memorial Institute
ES2247598T3 (es) * 1995-05-11 2006-03-01 University Of Utah Research Foundation Sustitutivo del tabaco.
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
EP1983827A4 (en) * 2006-02-01 2013-07-10 Stuart L Weg USE OF ANTIFUNGAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL CONDITIONS
US20160022643A1 (en) * 2014-07-22 2016-01-28 Professional Compounding Centers Of America Oral Transmucosal Compositions including Aromatase Inhibitors for Low Testosterone Levels in Men
WO2016053091A1 (en) * 2014-10-01 2016-04-07 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
EP3200773B1 (en) 2014-10-01 2018-07-18 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2022529353A (ja) 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2208120A (en) * 1938-03-02 1940-07-16 William B Coleman Pharmaceutical preparation and method of making same
US3943928A (en) * 1974-09-25 1976-03-16 Lariccia Anthony H Eliminating the safety hazard in oral dissolution of a solid
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4551329A (en) * 1984-01-20 1985-11-05 Joan Harris Oral medicament lollipop
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics

Also Published As

Publication number Publication date
AU6069794A (en) 1994-06-23
EP0493380B1 (en) 1997-10-29
AU5035290A (en) 1991-04-08
DK30092D0 (da) 1992-03-05
NO920855D0 (no) 1992-03-04
ATE159658T1 (de) 1997-11-15
NO920854L (no) 1992-04-27
NO920854D0 (no) 1992-03-04
AU645966B2 (en) 1994-02-03
EP0493380A1 (en) 1992-07-08
WO1991003233A1 (en) 1991-03-21
JPH05501854A (ja) 1993-04-08
DK30092A (da) 1992-05-05
EP0493380A4 (en) 1992-10-07
DE68928415D1 (de) 1997-12-04
JP2758985B2 (ja) 1998-05-28
DE68928415T2 (de) 1998-02-26
DK175773B1 (da) 2005-02-14

Similar Documents

Publication Publication Date Title
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
Kennedy et al. Intravenous regional analgesia: an appraisal
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
ES2186693T3 (es) Uso combinado del acido hialuronico y de agentes terapeuticos para mejorar el efecto terapeutico.
ATE111733T1 (de) Verwendung von nikotin zur herstellung eines kit zur behandlung von krankheitszuständen, die auf eine nikotinbehandlung ansprechen.
CA2041579A1 (en) Dosage form
JP2002532432A5 (no)
NO920855D0 (no) Medikamentinneholdende matrise
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
Bernstein et al. A clinical and electrophysiologic study of the treatment of painful diabetic neuropathies with pyridoxine
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
RU2000101091A (ru) Способ лечения дистрофических заболеваний сетчатки и зрительного нерва
Duhault et al. The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties. 2. Protective activity of S 1702 on the microvascular system in normal and diabetic rats
RU94018748A (ru) Лекарственный сбор для лечения больных с нарушениями сердечного ритма
EP0397211A3 (en) Percutaneous administration of 3'-azide-3'-deoxythymidine
CN2233753Y (zh) 护心袋
Reynolds et al. Circulatory versus respiratory deaths from pentothal sodium
CN2224631Y (zh) 药物保健袋
RU93034374A (ru) Лекарственный сбор для лечения ишемической болезни сердца, сопровождающейся выраженными невротическими реакциями
王小马 ELECTROIMPULSE ACUPUNCTURE TREATMENT OF 110 CASES OF ABDOMINAL PAIN AS A SEOUELA OF ABDOMINAL SURGERY
姚尊华 et al. OBSERVATION ON 52 CASES OF PARALYSIS OF COMMON PERONEAL NERVE TREATED BY ACUPUNCTURE AND PLUM-BLOSSOM NEEDLING
Aman et al. Clinical trial with glipizide in uncomplicated maturity onset diabetes mellitus